FDA warned UK website V10Suppliers.com for selling unapproved, misbranded opioid drugs to U.S. consumers.
What happened
FDA reviewed the website www.V10Suppliers.com and found it offering opioid prescription drugs, including tramadol and oxycodone, for sale to U.S. consumers. FDA said the products are unapproved new drugs and are misbranded because they are offered without a prescription and lack adequate directions for lay use.
What FDA found
Sold tramadol and oxycodone products that are not FDA-approved new drugs and have no approved applications in effect.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]Sold prescription opioid drugs with labeling that did not give adequate directions for safe use by a layperson, so they are misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]Offered prescription drugs for sale without requiring a prescription, which misbrands them while held for sale.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]Caused misbranded drugs to be introduced into interstate commerce by offering them for sale to U.S. consumers.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks V10Suppliers.com to stop offering unapproved and misbranded drugs to U.S. consumers and to respond in writing within 15 working days describing steps taken to fix the violations and prevent recurrence. If it cannot complete corrections in that time, it must state why and give a completion date.
Who should pay attention
- U.S. consumers who buy medicines online
- online sellers of prescription opioids to U.S. customers
- companies that ship, pay for, or advertise online drug sales
This is a summary. Read the original letter on fda.gov.